Common themes TRIPS flexibilities – Assertion and erosion of flexibilities – Legal and regulatory reform – Use of flexibilities: opposition has generated more success; CL less success – Political will to issue CLs? Opportunities + threats – EAC, EPO, Bangui reform etc

Common themes Shifting political contexts – Financing: Global Fund Round 11 cancellation, shrinking national budgets – Brazil, China and Russia FTAs – EU India – TPP – EU ASEAN – (Non EU countries FTAs)

Common themes Indian generic industry mergers, tie ins, buy outs “Next wave” of national threats – Training of judges – IP enforcement meetings [linkage to public health and safety/influence of NDRAs] – Regional IP meetings sponsored by WIPO – “Susan Finston” syndrome

Common themes Local production: what is happening in our countries – Capacity building – Regulatory, price, quality Voluntary licenses are taking the fight out of civil society – Civil society divisions – Defending middle income country markets for generic competition – De-toothing generic industry – Gives pharma rosy glow

Common themes Powerful activism, treatment literacy are crucial to our success – We have diverse political, capacity, mobilization experiences – Need stronger links between movements including non health movements; regionally and globally – Access to information

Campaign strategies Aggressive proactive national, regional and global campaign to: – Reform IP laws and policies – Expand tactical opposition efforts What will it take? Products and company; disease; FTA campaigns Kaletra campaign Novartis Supreme Court case Revisiting links with antiglobalization, other ‘allied’ movements